NCT05907759 2026-03-18
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
5 trialsNCT07308886 2026-03-18
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04305691 2026-02-27
Trial of Ixazomib for Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 2 Recruiting
NCT06445166 2025-08-28
Propranolol for the Treatment of Kaposi Sarcoma in Adults
Washington University School of Medicine
Phase 2 Recruiting
NCT03993106 2024-05-02
A Study of sEphB4-HSA in Kaposi Sarcoma
Vasgene Therapeutics, Inc
Phase 2 Recruiting